Tricking the tumour microenvironment into becoming our best rational drug design factory: reversal of immune suppression

Abstract

The immune cellular components of the tumour microenvironment are a diverse group of cells that paradoxically are now appreciated to have a coordinated opposing duality of either promoting or retarding tumour growth. Manipulating this seemingly dynamic interaction for therapeutic benefit is a hotbed of much research. Recent findings in tumour immunology (both preclinical and clinical) build on more than a century of insights and provide a way forward to improving patient outcomes, long term survival and the predictability of “cures”. This opinion piece attempts to summarise some of these historical and contemporary insights with a view to describing eminently testable therapeutic solutions.

Keywords

Tumour microenvironments / immune suppression / regulatory T cells / immune modulation / reversal / plasticity / spatio-temporal

References

[1] Fishbein M.Progress in medical science-IV.Scientific American1926;134:26-7

[2] The 2007-2008 President’s Cancer Panel Report. Available from: https://deainfo.nci.nih.gov/Advisory/pcp/archive/pcp07-08rpt/ExecSum.pdf [Last accessed on 25 Feb 2022]

[3] Hall SS. Commotion in the blood. Henry Holt and Company. 1998. p. 249.

[4] Beardsley T.A war not won.Scientific American1994;270:130-8

[5] Tuma RS.Large trials, small gains: is change on the way?.J Natl Cancer Inst2010;102:1216-17, 1223

[6] Hall SS. Commotion in the blood. Henry Holt and Company. 1998 p. 30.

[7] Hall SS. Commotion in the blood. Henry Holt and Company. 1998 p. 123.

[8] Janssen LME,Logsdon CD.The immune system in cancer metastasis: friend or foe?.J Immunother Cancer2017;5:79 PMCID:PMC5644253

[9] Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development.Nat Rev Cancer2006;6:24-37

[10] Burugu S,Nielsen TO.Emerging targets in cancer immunotherapy.Semin Cancer Biol2018;52:39-52

[11] Greten FR.Inflammation and cancer: triggers, mechanisms, and consequences.Immunity2019;51:27-41 PMCID:PMC6831096

[12] Lippitz BE.Cytokine patterns in patients with cancer: a systematic review.Lancet Oncol2013;14:e218-28

[13] Lippitz BE.Cytokine patterns in cancer patients: a review of the correlation between interleukin 6 and prognosis.Oncoimmunology2016;5:e1093722 PMCID:PMC4910721

[14] Ihde DC.Paraneoplastic syndromes.Hosp Pract (Off Ed)1987;22:105-12, 117

[15] Maverakis E,Wehrli LN,Garcia MS.The etiology of paraneoplastic autoimmunity.Clin Rev Allergy Immunol2012;42:135-44

[16] Whiteside TL.Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention.Semin Cancer Biol2006;16:3-15

[17] Stewart TJ.Improving cancer immunotherapy by targeting tumor-induced immune suppression.Cancer Metastasis Rev2011;30:125-40

[18] Davis MM.T-cell antigen receptor genes and T-cell recognition.Nature1988;334:395-402

[19] Macdonald IK,Chapman CJ.Autoantibodies: opportunities for early cancer detection.Trends Cancer2017;3:198-213

[20] Wu J,Song W.The roles and applications of autoantibodies in progression, diagnosis, treatment and prognosis of human malignant tumours.Autoimmun Rev2017;16:1270-81

[21] Schumacher TN.Neoantigens in cancer immunotherapy.Science2015;348:69-74

[22] Piersma SJ,van der Burg SH.Tumor-specific regulatory T cells in cancer patients.Hum Immunol2008;69:241-9

[23] Chauhan R.Inflammatory markers in cancer: potential resources.Front Biosci (Schol Ed)2020;12:1-24

[24] Hui L.Tumor microenvironment: sanctuary of the devil.Cancer Lett2015;368:7-13

[25] Anderson NM.The tumor microenvironment.Curr Biol2020;30:R921-5 PMCID:PMC8194051

[26] Quail DF.Microenvironmental regulation of tumor progression and metastasis.Nat Med2013;19:1423-37 PMCID:PMC3954707

[27] Yuan R,Geng H.Reversing the polarization of tumor-associated macrophages inhibits tumor metastasis.Int Immunopharmacol2017;49:30-7

[28] Poh AR.Targeting macrophages in cancer: from bench to bedside.Front Oncol2018;8:49 PMCID:PMC5858529

[29] Kumar V,Tcyganov E.The nature of myeloid-derived suppressor cells in the tumor microenvironment.Trends Immunol2016;37:208-20 PMCID:PMC4775398

[30] Berraondo P,Ochoa MC.Cytokines in clinical cancer immunotherapy.Br J Cancer2019;120:6-15 PMCID:PMC6325155

[31] Li L,Cai T.Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment.Int Immunopharmacol2020;88:106939

[32] Hoekstra ME,Schumacher TN.Modulation of the tumor micro-environment by CD8⁺ T cell-derived cytokines.Curr Opin Immunol2021;69:65-71 PMCID:PMC7610766

[33] Arenas-Ramirez N,Boyman O.Interleukin-2: biology, design and application.Trends Immunol2015;36:763-77

[34] Zaidi MR.The interferon-gamma paradox in cancer.J Interferon Cytokine Res2019;39:30-8 PMCID:PMC6350411

[35] Montfort A,Levade T,Meyer N.The TNF paradox in cancer progression and immunotherapy.Front Immunol2019;10:1818 PMCID:PMC6685295

[36] Coventry BJ.The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses.Cancer Manag Res2012;4:215-21 PMCID:PMC3421468

[37] Sakaguchi S,Asano M,Toda M.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.J Immunol1995;155:1151-64

[38] Kamada T,Tay C.PD-1⁺ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.Proc Natl Acad Sci U S A2019;116:9999-10008 PMCID:PMC6525547

[39] Marangoni F,Corsini M.Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop.Cell2021;184:3998-4015.e19 PMCID:PMC8664158

[40] Gratz IK,Maurano MM.Cutting edge: self-antigen controls the balance between effector and regulatory T cells in peripheral tissues.J Immunol2014;192:1351-5 PMCID:PMC3925257

[41] Pinheiro DF,Maurano MM.Cutting edge: tissue antigen expression levels fine-tune T cell differentiation decisions in vivo.J Immunol2020;205:2577-82 PMCID:PMC8606034

[42] Busse D,Hobiger K.Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments.Proc Natl Acad Sci U S A2010;107:3058-63 PMCID:PMC2840293

[43] McNally A,Sparwasser T,Steptoe RJ.CD4+CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasis.Proc Natl Acad Sci U S A2011;108:7529-34 PMCID:PMC3088596

[44] Challa DK,Lo ST,Ward ES.Antigen dynamics govern the induction of CD4(+) T cell tolerance during autoimmunity.J Autoimmun2016;72:84-94

[45] Pradeu T.The discontinuity theory of immunity.Sci Immunol2016;1:AAG0479 PMCID:PMC5321532

[46] Pradeu T.The danger theory: 20 years later.Front Immunol2012;3:287 PMCID:PMC3443751

[47] Kareva I.Immune suppression in pregnancy and cancer: parallels and insights.Transl Oncol2020;13:100759 PMCID:PMC7191218

[48] Bruno V,Baci D.Endometrial cancer immune escape mechanisms: let us learn from the fetal-maternal interface.Front Oncol2020;10:156 PMCID:PMC7080858

[49] Nottke A. Taming the cycle: how does the pill work? Available from: https://sitn.hms.harvard.edu/flash/2008/issue40/ [Last accessed on 25 Feb 2022]

[50] Flemming A.Cancer: tumour-specific ablation of Treg cells induces anticancer response.Nat Rev Drug Discov2016;15:676-7

[51] Ohue Y.Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?.Cancer Sci2019;110:2080-9 PMCID:PMC6609813

[52] Boyman O,Raeber ME.Modulation of T cell responses by IL-2 and IL-2 complexes.Clin Exp Rheumatol2015;33:S54-7

[53] Tran E,Rosenberg SA.‘Final common pathway’ of human cancer immunotherapy: targeting random somatic mutations.Nat Immunol2017;18:255-62 PMCID:PMC6295671

[54] Shimizu K,Okada M,Fujii SI.Immune suppression and reversal of the suppressive tumor microenvironment.Int Immunol2018;30:445-54

[55] Ahmed A.Targeting immunogenic cell death in cancer.Mol Oncol2020;14:2994-3006 PMCID:PMC7718954

[56] Vaes RDW,Vooijs M.Biomarkers of radiotherapy-induced immunogenic cell death.Cells2021;10:930 PMCID:PMC8073519

[57] Storozynsky Q.The impact of radiation-induced DNA damage on cGAS-STING-mediated immune responses to cancer.Int J Mol Sci2020;21:8877 PMCID:PMC7700321

[58] McLaughlin M,Pedersen M.Inflammatory microenvironment remodelling by tumour cells after radiotherapy.Nat Rev Cancer2020;20:203-17

[59] Xu W,Menzies AM.Intratumoural immunotherapies in oncology.Eur J Cancer2020;127:1-11

[60] Chavez M,Ingham ES.Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation.Theranostics2018;8:3611-28 PMCID:PMC6037035

[61] Yip YK,Oppenheim JD.Stimulation of human gamma interferon production by diterpene esters.Infect Immun1981;34:131-9 PMCID:PMC350832

[62] Ribas A,Puzanov I.Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy.Cell2017;170:1109-19.e10 PMCID:PMC8034392

[63] Tubin S,Salerno G,Yan W.Mono-institutional phase 2 study of innovative Stereotactic Body RadioTherapy targeting PArtial Tumor HYpoxic (SBRT-PATHY) clonogenic cells in unresectable bulky non-small cell lung cancer: profound non-targeted effects by sparing peri-tumoral immune microenvironment.Radiat Oncol2019;14:212 PMCID:PMC6878646

[64] Markovsky E,Samstein RM.An antitumor immune response is evoked by partial-volume single-dose radiation in 2 murine models.Int J Radiat Oncol Biol Phys2019;103:697-708 PMCID:PMC6764416

[65] Rodríguez-Ruiz ME,Melero I,Demaria S.Immunological mechanisms responsible for radiation-induced abscopal effect.Trends Immunol2018;39:644-55 PMCID:PMC6326574